# UNIVERSITY OF TX MD ANDERSON CAN CTR: RAPID: A patient-centric, investigator-initiated, Bayesian-designed, open-label, phase 2 platform trial of promising drugs for AYA patients with relapsed/refractory Ewing sarcoma & DSRCT.

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | UNIVERSITY OF TX MD ANDERSON CAN CTR |
| Location | HOUSTON, TX |
| Project | RAPID: A patient-centric, investigator-initiated, Bayesian-designed, open-label, phase 2 platform trial of promising drugs for AYA patients with relapsed/refractory Ewing sarcoma & DSRCT. |
| Project number | 1R01FD008794-01 |
| Mechanism | R01 |
| Institute | Food and Drug Administration |
| Award | $899,917 |
| Awarded | 2026-09-23 |
| Project period | 2026-07-01 to 2030-06-30 |
| UEI | S3GMKS8ELA16 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11440318). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.